EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial

Max Vaynrub, Meredith K Bartelstein, Victoria Y Yu, Yoshiya Yamada, Daniel R Gomez, Daniel E Prince, Zhigang Zhang, Stephanie M Lobaugh, Boris A Mueller, Michael B Bernstein, David M Guttmann, Divya Yerramilli und 1 weitere

Journal of the National Comprehensive Cancer Network · 2026-06 · 24 (6) · 265-270

DOI: 10.6004/jnccn.2025.7478 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-06. Verfasst von Max Vaynrub und 12 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Bone Neoplasms, Radiosurgery, Preoperative Care, Fractures, Spontaneous. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surgical stabilization followed by postoperative radiotherapy (RT) is the standard of care for impending pathologic fractures due to bone metastases. Compared with conventional RT, stereotactic body RT (SBRT) provides more durable tumor control and palliation, but treatment volume constraints often preclude postoperative use. Preoperative SBRT limited to the tumor volume offers a solution by delivering an ablative dose before intraoperative tumor dissemination, but its safety is not established.

Methods

We conducted a phase I, nonrandomized clinical trial at a quaternary care cancer center, with accrual between June 2021 and April 2024. Eligible patients (N=38) had pelvic or long bone metastases with impending pathologic fractures requiring surgical stabilization. Patients received preoperative SBRT (27–30 Gy in 3 fractions or 18–24 Gy in 1 fraction) followed by surgical stabilization within 1 week. The primary endpoint was rate of wound complications within 6 weeks after preoperative SBRT and surgical stabilization. Secondary endpoints were rates of tumor recurrence and grade ≥3 treatment-related toxicities within 1 year.

Results

A total of 7 patients were excluded due to inability to receive treatment or death prior to the primary endpoint. Thirty-one patients were evaluated at 6 weeks postoperatively, 26 at 3 months, and 16 at 1 year. The median age was 66 years (IQR, 59–71), and 15 (48%) patients were male. At 6 weeks, 2 of 31 patients (6.5%; 95% CI, 0.79–21.4) experienced wound complications. At 3 months, 1 of 26 patients (3.8%; 95% CI, 0.10–19.6) experienced grade ≥3 treatment-related toxicity. At 12 months, 1 of 16 patients (6.3%; 95% CI, 0.16–30.2) had tumor recurrence.

Conclusions

Preoperative SBRT is associated with a low risk of wound complications and durable local tumor control. A randomized controlled trial examining its efficacy, potential to facilitate less invasive surgery, and impact on functional outcomes is warranted. ClinicalTrials.gov identifier: NCT05038124

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsRadiosurgeryPreoperative CareFractures, SpontaneousHumansMaleFemaleMiddle AgedAgedTreatment Outcome

Autor:innen und Institutionen

  • 1Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • 2Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • 3Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • 4Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • 5Department of Radiation Oncology, New York University Langone Health, New York, NY.

Förderung

  • NCI NIH HHS

Zitieren

APA

Vaynrub, M., Bartelstein, M. K., Yu, V. Y., Yamada, Y., Gomez, D. R., Prince, D. E., Zhang, Z., Lobaugh, S. M., Mueller, B. A., Bernstein, M. B., Guttmann, D. M., Yerramilli, D., & Yang, J. T. (2026). Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial. Journal of the National Comprehensive Cancer Network, 24(6), 265-270. https://doi.org/10.6004/jnccn.2025.7478

Vancouver

Vaynrub M, Bartelstein MK, Yu VY, Yamada Y, Gomez DR, Prince DE, et al. Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial. Journal of the National Comprehensive Cancer Network. 2026;24(6):265-270. doi:10.6004/jnccn.2025.7478

BibTeX
@article{Vaynrub2026,
  author = {Vaynrub, Max and Bartelstein, Meredith K and Yu, Victoria Y and Yamada, Yoshiya and Gomez, Daniel R and Prince, Daniel E and Zhang, Zhigang and Lobaugh, Stephanie M and Mueller, Boris A and Bernstein, Michael B and Guttmann, David M and Yerramilli, Divya and Yang, Jonathan T},
  title = {Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {6},
  pages = {265--270},
  doi = {10.6004/jnccn.2025.7478}
}
Kostenlos starten →